• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Aerie Pharmaceuticals Inc.

    11/21/22 11:33:59 AM ET
    $AERI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AERI alert in real time by email
    S-8 POS 1 brhc10044429_s8pos.htm S-8 POS
    As filed with the Securities and Exchange Commission on November 21, 2022
     
    Registration No. 333-216578
    Registration No. 333-219671
    Registration No. 333-221442
    Registration No. 333-223364
    Registration No. 333-263504

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     
    Post-Effective Amendment No. 1 to:
    Form S-8 Registration Statement No. 333-216578
     
    Post-Effective Amendment No. 1 to:
    Form S-8 Registration Statement No. 333-219671
     
    Post-Effective Amendment No. 1 to:
    Form S-8 Registration Statement No. 333-221442
     
    Post-Effective Amendment No. 1 to:
    Form S-8 Registration Statement No. 333-223364
     
    Post-Effective Amendment No. 1 to:
    Form S-8 Registration Statement No. 333-263504
     
    UNDER
    THE SECURITIES ACT OF 1933

    AERIE PHARMACEUTICALS, INC.
    (Exact Name of Registrant as Specified in Its Charter)
     
    Delaware
     
    20-3109565
    (State or Other Jurisdiction of Incorporation or Organization)
     
    (I.R.S. Employer Identification No.)

    4301 Emperor Blvd., Suite 400
    Durham, North Carolina 27703
    (Address of Principal Executive Offices, Including Zip Code)
     
    AERIE PHARMACEUTICALS, INC. INDUCEMENT AWARD PLAN
    AERIE PHARMACEUTICALS, INC. AMENDED AND RESTATED INDUCEMENT AWARD PLAN
    AERIE PHARMACEUTICALS, INC. SECOND AMENDED AND RESTATED INDUCEMENT AWARD PLAN
    (Full Title of the Plan)
     
    Royce Bedward
    Senior Vice President, General Counsel
    Aerie Pharmaceuticals, Inc.
    6201 South Freeway
    Fort Worth, Texas 76134
    (817) 293-0450
    (Name, address and telephone number, including area code, of agent for service)
     
    Copies to:
     
    Graham Robinson
    Faiz Ahmad
    Skadden, Arps, Slate, Meagher & Flom LLP
    500 Boylston Street
    Boston, Massachusetts 02116
    (617) 573-4800
     
    Tom Hudnall
    Assistant Secretary
    Aerie Pharmaceuticals, Inc.
    6201 South Freeway
    Fort Worth, Texas 76134
    (817) 293-0450



    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer
    ☒
    Accelerated filer
    ☐
    Non-accelerated filer
    ☐
    Smaller reporting company
    ☐
       
    Emerging growth company
    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐



    EXPLANATORY NOTE — DEREGISTRATION OF SECURITIES
     
    This Post-Effective Amendment relates to the following Registration Statements on Form S-8 (collectively, the “Registration Statements”), originally filed with the Securities and Exchange Commission (the “SEC”) by Aerie Pharmaceuticals, Inc., a Delaware corporation (the “Registrant”):
     

    •
    Registration Statement on Form S-8 (File No. 333-216578), filed with the SEC on March 9, 2017, registering 418,000 shares of common stock, $0.001 par value per share, under the Aerie Pharmaceuticals, Inc. Inducement Award Plan.

    •
    Registration Statement on Form S-8 (File No. 333-219671), filed with the SEC on August 3, 2017, registering 463,500 shares of common stock, $0.001 par value per share, under the Aerie Pharmaceuticals, Inc. Inducement Award Plan.

    •
    Registration Statement on Form S-8 (File No. 333-221442), filed with the SEC on November 9, 2017, registering 83,700 shares of common stock, $0.001 par value per share, under the Aerie Pharmaceuticals, Inc. Amended and Restated Inducement Award Plan.

    •
    Registration Statement on Form S-8 (File No. 333-223364), filed with the SEC on March 1, 2018, registering 327,300 shares of common stock, $0.001 par value per share, under the Aerie Pharmaceuticals, Inc. Second Amended and Restated Inducement Award Plan.

    •
    Registration Statement on Form S-8 (File No. 333-263504), filed with the SEC on March 11, 2022, registering 2,700,000 shares of common stock, $0.001 par value per share, under the Aerie Pharmaceuticals, Inc. Second Amended and Restated Inducement Award Plan.
     
    Pursuant to the Agreement and Plan of Merger, dated as of August 22, 2022, among the Registrant, Alcon Research, LLC (“Parent”), and Lyon Merger Sub, Inc. (“Merger Sub”),  Merger Sub merged with and into the Registrant (the “Merger”) on November 21, 2022, with the Registrant becoming a wholly-owned subsidiary of Parent as of the effective time of the Merger.   At the effective time of the Merger, each outstanding share of common stock of the Registrant was converted into the right to receive $15.25 in cash (in the case of outstanding stock options, less the exercise price for the applicable shares of common stock underlying the stock option), without interest and subject to required withholding taxes.
     
    As a result of the Merger, the Registrant has terminated all offerings of the Registrant’s securities pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statements.  In accordance with undertakings made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities that have been registered for issuance that remain unsold at the termination of the offering, the Registrant hereby removes from registration all of such securities of the Registrant registered but not sold or otherwise issued under the Registration Statements, if any, as of the date hereof. Each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities, and the Registrant hereby terminates the effectiveness of each Registration Statement.
     

    SIGNATURES
     
    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Durham, State of North Carolina, on November 21, 2022.
     
     
    AERIE PHARMACEUTICALS, INC.
         
     
    By:
    /s/ Tom Hudnall  
       
    Name: Tom Hudnall
       
    Title: Assistant Secretary

    No other person is required to sign this Post-Effective Amendment to the Registration Statements in reliance upon Rule 478 under the Securities Act of 1933, as amended.



    Get the next $AERI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AERI

    DatePrice TargetRatingAnalyst
    8/29/2022$14.00 → $15.25Buy → Neutral
    Citigroup
    8/23/2022Buy → Hold
    Needham
    8/23/2022$30.00 → $15.25Overweight → Neutral
    Cantor Fitzgerald
    2/25/2022$22.00 → $14.00Buy
    Needham
    11/5/2021$24.00 → $22.00Buy
    Needham
    8/5/2021$26.00 → $24.00Buy
    Needham
    More analyst ratings

    $AERI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company's Ophthalmic Pharmaceutical Business

      Leveraging Alcon's robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Alcon's presence in the $20 billion global ophthalmic pharmaceutical category1 Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has completed its acquisition of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI, "Aerie"))). This transaction helps bolster Alcon's presence in the ophthalmic pharmaceutical space with its growing portfolio of commercial products and development pi

      11/22/22 1:01:00 AM ET
      $AERI
      $ALC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Ophthalmic Goods
    • Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results

      Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the third quarter ended September 30, 2022. "Aerie delivered another solid performance in the third quarter and executed well across our three strategic pillars of growth. Our first-in-class glaucoma franchise showed strong continued year-over-year growth, in line with our expect

      11/3/22 4:01:00 PM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options

      Webinar to be held Friday, September 23, 2022 @ 10 a.m. ET Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that it will host a Key Opinion Leader (KOL) webinar on Friday, September 23, 2022 from 10:00 a.m. – 11:30 a.m. Eastern Time. The event will feature Dr. Laura Periman, MD, of the Periman Eye Institute, and Dr. John Sheppard, MD, of the Virginia Eye Consultants, who will discuss New Perspectives on Dry Eye Disease (DED), including the Current Landscape, Unmet Medical Needs, and Emerging Treatment Options, including Aerie's investigational TRPM8 agoni

      9/13/22 8:00:00 AM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AERI
    Financials

    Live finance-specific insights

    See more
    • Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company's Ophthalmic Pharmaceutical Business

      Leveraging Alcon's robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Alcon's presence in the $20 billion global ophthalmic pharmaceutical category1 Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has completed its acquisition of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI, "Aerie"))). This transaction helps bolster Alcon's presence in the ophthalmic pharmaceutical space with its growing portfolio of commercial products and development pi

      11/22/22 1:01:00 AM ET
      $AERI
      $ALC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Ophthalmic Goods
    • Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results

      Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the third quarter ended September 30, 2022. "Aerie delivered another solid performance in the third quarter and executed well across our three strategic pillars of growth. Our first-in-class glaucoma franchise showed strong continued year-over-year growth, in line with our expect

      11/3/22 4:01:00 PM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio

      Builds on Alcon's existing commercial expertise in the estimated $20 billion global ophthalmic pharmaceutical segment1 Adds Rocklatan® and Rhopressa®, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates Transaction values Aerie at approximately $770 million in equity value and is expected to be accretive to Alcon's core diluted EPS in 2024 Ad hoc announcement pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and Aerie Pharmaceuticals, Inc. (NASDAQ:AERI, "Aerie"))), a pharmaceutical company focused on the discovery, development, manufacturing and commercialization of first-in

      8/22/22 9:18:00 PM ET
      $AERI
      $ALC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Ophthalmic Goods

    $AERI
    SEC Filings

    See more
    • SEC Form 15-12G filed by Aerie Pharmaceuticals Inc.

      15-12G - AERIE PHARMACEUTICALS INC (0001337553) (Filer)

      12/1/22 3:07:11 PM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Aerie Pharmaceuticals Inc.

      S-8 POS - AERIE PHARMACEUTICALS INC (0001337553) (Filer)

      11/21/22 11:55:29 AM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Aerie Pharmaceuticals Inc.

      S-8 POS - AERIE PHARMACEUTICALS INC (0001337553) (Filer)

      11/21/22 11:52:52 AM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AERI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aerie Pharma downgraded by Citigroup with a new price target

      Citigroup downgraded Aerie Pharma from Buy to Neutral and set a new price target of $15.25 from $14.00 previously

      8/29/22 7:08:38 AM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aerie Pharma downgraded by Needham

      Needham downgraded Aerie Pharma from Buy to Hold

      8/23/22 8:56:43 AM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aerie Pharma downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded Aerie Pharma from Overweight to Neutral and set a new price target of $15.25 from $30.00 previously

      8/23/22 7:09:23 AM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AERI
    Leadership Updates

    Live Leadership Updates

    See more
    • Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer

      Finance executive with a successful track record in capital creation, deployment, and optimization Brings breadth of finance, strategy and business development experience Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Peter F. Lang will join the Company as Chief Financial Officer, effective March 18, 2022. He will report to Raj Kannan, Chief Executive Officer of Aerie Pharmaceuticals and become a member of the Aerie Executive Committee. "I am pleased to welcome Peter to our leadership team," said Raj Kannan, Chief Executive Officer. "His extensive e

      3/18/22 7:00:00 AM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aerie Pharmaceuticals Appoints Gary Sternberg, M.D., M.B.A. as Chief Medical Officer

      Fellowship-trained Ophthalmologist and well-rounded biopharmaceutical executive brings breadth of clinical development, medical affairs, strategy, and business development experience Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Gary Sternberg, M.D., M.B.A., will join the Company as Chief Medical Officer (CMO), effective March 1, 2022. He will report to Raj Kannan, Chief Executive Officer of Aerie Pharmaceuticals and become a member of the Aerie Executive Committee. Gary is an Ophthalmologist who is fellowship trained in cornea and external disease

      2/24/22 6:30:00 AM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer

      An accomplished leader Brings a depth and breadth of commercial, business development, and portfolio strategy experience Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today announced that Raj Kannan will join the Company as Chief Executive Officer and a director, effective December 20, 2021. "On behalf of the Board of Directors, I am very pleased to welcome Raj Kannan to Aerie. During the search process, the Board was pleased to interview several strong candidates and Raj rose to the top of the list during the process. Raj brings a track record of building effective organizations and teams, launching and growing products in the U.S. and globally, buildi

      12/16/21 6:30:00 AM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AERI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Mchugh Julie returned $245,449 worth of shares to the company (16,095 units at $15.25), closing all direct ownership in the company to cover taxes

      4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)

      11/21/22 4:59:15 PM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Mcgraw Benjamin F Iii returned $640,256 worth of shares to the company (41,984 units at $15.25), closing all direct ownership in the company to satisfy tax liability

      4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)

      11/21/22 4:57:44 PM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Mcdonnell Peter J returned $121,924 worth of shares to the company (7,995 units at $15.25), closing all direct ownership in the company (for withholding tax)

      4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)

      11/21/22 4:56:06 PM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AERI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Aerie Pharmaceuticals Inc. (Amendment)

      SC 13G/A - AERIE PHARMACEUTICALS INC (0001337553) (Subject)

      2/10/23 10:00:04 AM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Aerie Pharmaceuticals Inc. (Amendment)

      SC 13G/A - AERIE PHARMACEUTICALS INC (0001337553) (Subject)

      11/10/22 4:06:40 PM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Aerie Pharmaceuticals Inc. (Amendment)

      SC 13G/A - AERIE PHARMACEUTICALS INC (0001337553) (Subject)

      2/14/22 12:39:59 PM ET
      $AERI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care